Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series

We recently reported that neoadjuvant 5-FU, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel and/or trastuzumab induced a high pathological complete response (pCR) rate in hormone-negative patients. The present study examined the therapeutic efficacy of neoadjuvant FEC followed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiba, Takayoshi, Morii, Nao, Takahashi, Hirotoshi, Ozaki, Shinji, Atsumi, Misao, Masumoto, Fumi, Yamashiro, Hiroyasu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559240/
https://www.ncbi.nlm.nih.gov/pubmed/26357489
http://dx.doi.org/10.2147/BCTT.S90975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559240/
https://www.ncbi.nlm.nih.gov/pubmed/26357489
http://dx.doi.org/10.2147/BCTT.S90975

Ejemplares similares